Tokyo, Japan

Hirobumi Sakita

This inventor holds 1 USPTO granted patent. Top assignee: Anne Company Limited. Active years: 1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hirobumi Sakita. Retrieved from https://idiyas.com/inventor/hirobumi-sakita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Hirobumi Sakita

Introduction

Hirobumi Sakita is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of medical technology. His work focuses on improving healthcare solutions through innovative inventions.

Latest Patents

Hirobumi Sakita holds a patent for an endometrial cell sampler. This invention aims to enhance the process of collecting endometrial cells for medical analysis. It represents a step forward in diagnostic procedures, providing more accurate and efficient sampling methods.

Career Highlights

Sakita is currently employed at Anne Company Limited, where he continues to develop innovative medical technologies. His dedication to research and development has positioned him as a key figure in his field. With 1 patent to his name, he exemplifies the spirit of innovation that drives progress in healthcare.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Hirobumi Sakita's contributions to medical technology through his patent for an endometrial cell sampler highlight his commitment to innovation. His work at Anne Company Limited continues to pave the way for advancements in healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…